Drug Costs Are Spiking and It’s Not Clear Why

Pharmacists want Congress to investigate a sharp increase in medicinal costs.

A pharmacist pours Truvada pills back into the bottle at Jack's Pharmacy on November 23, 2010 in San Anselmo, California.
National Journal
Clara Ritger
See more stories about...
Clara Ritger
Jan. 31, 2014, 12:05 a.m.

Drug costs are rising, but in the opaque world of health care pri­cing, fig­ur­ing out what’s driv­ing the in­crease has be­come dif­fi­cult — if not im­possible.

Non­ethe­less, phar­macists want Con­gress to try. Vexed by triple- or quad­ruple-di­git per­cent in­creases in drug costs, the Na­tion­al Com­munity Phar­macists As­so­ci­ation is ask­ing law­makers to hold a hear­ing to find out why.

The prob­lem, the group says, is that phar­macists are get­ting gouged. Phar­macists try­ing to get their hands on gen­er­ic drugs such as Pravast­at­in, a drug for pa­tients with high cho­les­ter­ol, or the an­it­bi­ot­ic Doxy­cyc­line faced price spikes up­wards of 1,000 per­cent in 2013, ac­cord­ing to a sur­vey by the group.

Some 77 per­cent of phar­macists sur­veyed by the as­so­ci­ation said in the last six months of 2013 they ex­per­i­enced 26 or more in­stances of a large up­swing in the ac­quis­i­tion price of a gen­er­ic drug.

An ad­di­tion­al 84 per­cent said the price fluc­tu­ations im­peded their abil­ity to provide care and re­main in busi­ness, as some com­munity phar­ma­cies could not fill pre­scrip­tions that would res­ult in losses and some pa­tients de­clined med­ic­a­tion that would have emp­tied their wal­lets.

The find­ings are con­sist­ent with re­ports na­tion­wide that gen­er­ic-drug prices are ex­per­i­en­cing bank-break­ing price in­creases. Health care and phar­ma­ceut­ic­al con­sult­ing firm Pem­broke Con­sult­ing, for in­stance, found that with­in the last year, more than a dozen drugs hit prices 10 times their stand­ard rate. NCPA wants Con­gress to hold a hear­ing to find out what’s driv­ing the price points and wheth­er any­thing can be done by the feds to stop the trend.

But one primary-care doc­tor, Dav­id Belk, says he’s sus­pi­cious that the fault lies with drug com­pan­ies. The San Fran­cisco-based blog­ger has ob­served price jumps in single doses of med­ic­a­tion, where one size dosage of a drug was very ex­pens­ive and the oth­er dosages of that same drug were at a more reas­on­able cost.

Belk took a clip of the Costco web­site after he saw the gen­er­ic drug Irbe­sartan, a med­ic­a­tion for high blood pres­sure, hit nearly $300 for a 90-day sup­ply of the 150 mg tab­let. Yet for the 90-day sup­ply of the 300 mg tab­let, con­sumers paid only $30.

“If you ask the phar­ma­ceut­ic­al com­pany, they’ll say ‘Oh, we had a short­age,’ ” Belk said, “which makes no sense be­cause they were mak­ing oth­er mil­li­grams. By the time the phar­macy has figured out the price spiked, it’s dropped back down again.”

That trend, Belk said, leaves phar­ma­cies hanging out to dry with the ex­tra cost.

“Most doc­tors are pre­scrib­ing on the basis of the last drug rep they went to lunch with,” he said. “I think you would fix a lot of it if every­one had to ad­vert­ise their price.”

While Belk pro­poses to turn pa­tients in­to edu­cated con­sumers by cre­at­ing trans­par­ency about pre­scrip­tion drug costs at the doc­tor’s of­fice, the prob­lem re­mains that phar­macists can’t place their fin­ger on why gen­er­ic drugs seem to cost more than they used to—or at least, ex­per­i­ence ex­treme price vari­ations throughout the year.

Dan Mendel­son, CEO of con­sult­ing firm Avalere Health, cred­its the ef­fect­ive­ness and pop­ular­ity of gen­er­ic drugs as one reas­on phar­ma­ceut­ic­al com­pan­ies are able to charge more.

“I think that as de­mand for gen­er­ic drugs has gone up, it’s not sur­pris­ing to see that price has gone up as well,” Mendel­son said. “This is an un­reg­u­lated mar­ket in the sense that no one is telling them what to charge. You’re go­ing to see them cozy up to the price of the brand name product for com­pet­i­tion reas­ons.”

Mendel­son said his prob­lem with get­ting Con­gress in­volved in the situ­ation is that it sug­gests they should step in­to the mar­ket and im­pose price con­trols. Some­times, he said, the spikes are eas­ily ex­plained, such as when Doxy­cyc­line ex­per­i­enced a man­u­fac­tur­ing prob­lem and had a tem­por­ary short­age.

“I think people will con­tin­ue to use these gen­er­ic products be­cause they’re cost ef­fect­ive and needed when pre­scribed,” Mendel­son said. “There’s no ques­tion in my mind de­mand is go­ing to go up be­cause of the Af­ford­able Care Act, and these mar­kets re­spond to de­mand.”

Even high­er prices for gen­er­ics could be on the ho­ri­zon, as all health plans offered on the Af­ford­able Care Act ex­changes must cov­er pre­scrip­tion drugs, which could in­crease use and de­mand among con­sumers.

The Af­ford­able Care Act, however, doesn’t in­clude any spe­cif­ic pro­vi­sions to re­duce the over­all cost of drugs. But gen­er­ics are still cheap­er than their brand-name coun­ter­parts. And with more pat­ents for block­buster drugs set to ex­pire by 2018, they’ll con­tin­ue to be a com­pet­it­ive op­tion on the mar­ket.

What We're Following See More »
STAFF PICKS
These (Supposed) Iowa and NH Escorts Tell All
30 minutes ago
NATIONAL JOURNAL AFTER DARK

Before we get to the specifics of this exposé about escorts working the Iowa and New Hampshire primary crowds, let’s get three things out of the way: 1.) It’s from Cosmopolitan; 2.) most of the women quoted use fake (if colorful) names; and 3.) again, it’s from Cosmopolitan. That said, here’s what we learned:

  • Business was booming: one escort who says she typically gets two inquiries a weekend got 15 requests in the pre-primary weekend.
  • Their primary season clientele is a bit older than normal—”40s through mid-60s, compared with mostly twentysomething regulars” and “they’ve clearly done this before.”
  • They seemed more nervous than other clients, because “the stakes are higher when you’re working for a possible future president” but “all practiced impeccable manners.”
  • One escort “typically enjoy[s] the company of Democrats more, just because I feel like our views line up a lot more.”
Source:
STATE VS. FEDERAL
Restoring Some Sanity to Encryption
30 minutes ago
WHY WE CARE

No matter where you stand on mandating companies to include a backdoor in encryption technologies, it doesn’t make sense to allow that decision to be made on a state level. “The problem with state-level legislation of this nature is that it manages to be both wildly impractical and entirely unenforceable,” writes Brian Barrett at Wired. There is a solution to this problem. “California Congressman Ted Lieu has introduced the ‘Ensuring National Constitutional Rights for Your Private Telecommunications Act of 2016,’ which we’ll call ENCRYPT. It’s a short, straightforward bill with a simple aim: to preempt states from attempting to implement their own anti-encryption policies at a state level.”

Source:
STAFF PICKS
What the Current Crop of Candidates Could Learn from JFK
30 minutes ago
WHY WE CARE

Much has been made of David Brooks’s recent New York Times column, in which confesses to missing already the civility and humanity of Barack Obama, compared to who might take his place. In NewYorker.com, Jeffrey Frank reminds us how critical such attributes are to foreign policy. “It’s hard to imagine Kennedy so casually referring to the leader of Russia as a gangster or a thug. For that matter, it’s hard to imagine any president comparing the Russian leader to Hitler [as] Hillary Clinton did at a private fund-raiser. … Kennedy, who always worried that miscalculation could lead to war, paid close attention to the language of diplomacy.”

Source:
STAFF PICKS
Hillary Is Running Against the Bill of 1992
30 minutes ago
WHY WE CARE

The New Covenant. The Third Way. The Democratic Leadership Council style. Call it what you will, but whatever centrist triangulation Bill Clinton embraced in 1992, Hillary Clinton wants no part of it in 2016. Writing for Bloomberg, Sasha Issenberg and Margaret Talev explore how Hillary’s campaign has “diverged pointedly” from what made Bill so successful: “For Hillary to survive, Clintonism had to die.” Bill’s positions in 1992—from capital punishment to free trade—“represented a carefully calibrated diversion from the liberal orthodoxy of the previous decade.” But in New Hampshire, Hillary “worked to juggle nostalgia for past Clinton primary campaigns in the state with the fact that the Bill of 1992 or the Hillary of 2008 would likely be a marginal figure within today’s Democratic politics.”

Source:
STAFF PICKS
Trevor Noah Needs to Find His Voice. And Fast.
1 hours ago
WHY WE CARE

At first, “it was pleasant” to see Trevor Noah “smiling away and deeply dimpling in the Stewart seat, the seat that had lately grown gray hairs,” writes The Atlantic‘s James Parker in assessing the new host of the once-indispensable Daily Show. But where Jon Stewart was a heavyweight, Noah is “a very able lightweight, [who] needs time too. But he won’t get any. As a culture, we’re not about to nurture this talent, to give it room to grow. Our patience was exhausted long ago, by some other guy. We’re going to pass judgment and move on. There’s a reason Simon Cowell is so rich. Impress us today or get thee hence. So it comes to this: It’s now or never, Trevor.”

Source:
×